Povan

(Pyrvinium)

Phase 2Small molecule

PParkedale

Povan is one of 4 small molecule programs targeting Precancerous Condition. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Precancerous ConditionActive, not recruiting

Precancerous ConditionPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Precancerous Condition

#DrugCompanyPhaseTrials

Celebrex

PPhiladelphia Eye Associates

Approved

—2

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—3

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Povan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

APL

NCT06590454

Q4 2029

Phase 2Not yet recruiting

Precancerous Condition

NCT06782048

Clinical

Trials by Indication[1]

APL1 trial

REVerse Intestinal Metaplasia in the Stomach (REVISE)

Recruiting·KKatherine Garman·Phase 2·NCT06590454·32 enrolled

Precancerous Condition1 trial

Use of Pyrvinium to Reverse Stomach Precancerous Conditions

Not yet recruiting·NNational University Hospital, Singapore·Phase 2·NCT06782048·50 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

POVAN

NDA NDA011964

Jan 1, 1982

POVAN

NDA NDA012485

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pyrvinium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pyrvinium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pyrvinium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011964). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Parkedale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PParkedale

Povan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

APL1 trial

Precancerous Condition1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News